NewEdge Wealth LLC Has $1.58 Million Stock Position in Sanofi (NASDAQ:SNY)

NewEdge Wealth LLC boosted its position in Sanofi (NASDAQ:SNY) by 20.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,799 shares of the company’s stock after buying an additional 5,591 shares during the quarter. NewEdge Wealth LLC’s holdings in Sanofi were worth $1,582,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. boosted its stake in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Sunbelt Securities Inc. grew its holdings in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares during the last quarter. Sierra Ocean LLC bought a new position in Sanofi in the 4th quarter worth approximately $44,000. Finally, Versant Capital Management Inc bought a new position in Sanofi in the 4th quarter worth approximately $54,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

SNY opened at $54.47 on Friday. The stock’s 50 day simple moving average is $51.65 and its 200-day simple moving average is $52.60. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market cap of $138.24 billion, a PE ratio of 21.88, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

SNY has been the topic of several research analyst reports. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.